The baculovirus expression vector system: a modern technology for the future of influenza vaccine manufacturing

被引:19
|
作者
Trombetta, Claudia Maria [1 ]
Marchi, Serena [1 ]
Montomoli, Emanuele [1 ,2 ,3 ]
机构
[1] Univ Siena, Dept Mol & Dev Med, Siena, Italy
[2] VisMederi Srl, Siena, Italy
[3] VisMederi Res Srl, Siena, Italy
关键词
Influenza vaccines; egg-based technology; cell-culture platform; recombinant DNA technology; baculovirus expression vector system; MESSENGER-RNA VACCINES; PROTEIN N-GLYCOSYLATION; DOSE-RELATED SAFETY; VIRUS HEMAGGLUTININ; DOUBLE-BLIND; PROTECTIVE EFFICACY; ANTIBODY-RESPONSES; HEALTHY-ADULTS; INSECT CELLS; IMMUNOGENICITY;
D O I
10.1080/14760584.2022.2085565
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Introduction Influenza is a vaccine-preventable disease. Due to the evolving nature of influenza viruses, the composition of vaccines has to be updated annually. Most of the current influenza vaccines are still produced in embryonated chicken eggs, a well-established process with some limitations. Area covered This review focuses on the recombinant DNA technology using baculovirus expression vector system a modern method of manufacturing licensed influenza vaccines. The speed, scalability, biosafety and flexibility of the process, together with the reliability of the hemagglutinin in the vaccine, represent a significant advance toward new platforms for vaccine production. Expert opinion The scenario of vaccine production in the next years seems to be particularly interesting, involving a transition from the current egg-based production to new technologies, such as the cell culture platform, the RNA technology, the plant-based system, and the DNA vaccine. This latter offers great advantages over egg- and cell-based influenza vaccine production. The universal vaccine remains the goal of researchers and ideally would avoid the need for annual reformulation and re-administration of seasonal vaccines. The lesson learned from the COVID-19 pandemic highlights the importance of having different technologies available and able to promptly respond to a great demand of vaccines worldwide.
引用
收藏
页码:1233 / 1242
页数:10
相关论文
共 50 条
  • [31] Production of Lyssavirus proteins in the baculovirus expression system and their use as potential vaccine
    Drings, A
    Chambert, B
    Jallet, C
    Tordo, N
    Perrin, P
    Jacob, Y
    ANIMAL CELL TECHNOLOGY: FROM VACCINES TO GENETIC MEDICINE, 1997, : 191 - 195
  • [32] Increased productivity of the baculovirus expression vector system by combining enhancing factors
    Lee, Ji-Hoon
    Gwak, Won-Seok
    Bae, Sung-Min
    Choi, Jae-Bang
    Han, Beom-Ku
    Woo, Soo-Dong
    JOURNAL OF ASIA-PACIFIC ENTOMOLOGY, 2018, 21 (03) : 1079 - 1084
  • [33] OVEREXPRESSION OF PLANT HISTIDINOL DEHYDROGENASE USING A BACULOVIRUS EXPRESSION VECTOR SYSTEM
    NAGAI, A
    SUZUKI, K
    WARD, E
    MOYER, M
    HASHIMOTO, M
    MANO, J
    OHTA, D
    SCHEIDEGGER, A
    ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1992, 295 (02) : 235 - 239
  • [34] EXPRESSION OF ALEUTIAN MINK DISEASE PARVOVIRUS PROTEINS IN A BACULOVIRUS VECTOR SYSTEM
    CHRISTENSEN, J
    STORGAARD, T
    BLOCH, B
    ALEXANDERSEN, S
    AASTED, B
    JOURNAL OF VIROLOGY, 1993, 67 (01) : 229 - 238
  • [36] Gene gymnastics Synthetic biology for baculovirus expression vector system engineering
    Vijayachandran, Lakshmi S.
    Raj, Deepak B. Thimiri Govinda
    Edelweiss, Evelina
    Gupta, Kapil
    Maier, Josef
    Gordeliy, Valentin
    Fitzgerald, Daniel J.
    Berger, Imre
    BIOENGINEERED, 2013, 4 (05) : 279 - 287
  • [37] Production of recombinant proteins using the Baculovirus expression vector system.
    Crossen, R
    Gruenwald, S
    FASEB JOURNAL, 1998, 12 (05): : A1118 - A1118
  • [39] Production of recombinant proteins using the Baculovirus expression vector system.
    不详
    FASEB JOURNAL, 1999, 13 (07): : A1593 - A1593
  • [40] Production of Recombinant PRMT Proteins using the Baculovirus Expression Vector System
    Hutchinson, Ashley
    Seitova, Almagul
    JOVE-JOURNAL OF VISUALIZED EXPERIMENTS, 2021, (173):